News



  • Valneva Reports Further Positive Results for Its Chikungunya Vaccine Candidate2019-05-22

    Valneva Reports Further Positive Results for Its Chikungunya Vaccine Candidate

    Phase 1 unblinded results up to month 7 showed an excellent immunogenicity and safety profile confirming Valneva´s unique, single-shot vaccine candidate


    These results strongly support further development acceleration

    VLA1553 was generally safe in all dose groups
    • Well-tolerated in the low and medium dose. (Superior safety profile, including viremia, compared to the high dose group)
    • Excellent local tolerability
    Excellent immunogenicity profile in all dose groups after a single vaccination
    • 100% Seroconversion1 achieved at Day 14 after a single vaccination in all dose groups
    • Sustained at 100% after six months

    Saint Herblain (France), May 22, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced further positive Phase 1 results for its chikungunya vaccine candidate, VLA1553.

    PDF Download
    auf Deutsch lesen
  • Valneva Reports Strong Q1 2019 Operating Results and Advances Key R&D Programs towards Major Milestones2019-05-02

    Valneva Reports Strong Q1 2019 Operating Results and Advances Key R&D Programs towards Major Milestones

    Repeated significant growth in IXIARO® revenues; Lyme disease and chikungunya programs advancing towards major data points; R&D investor day planned for July in New York

    Strong financial results in Q1 2019
    • Product sales revenue of €32.8 million in Q1 2019, representing 9% growth at constant exchange rate (CER)
    •     Significant growth in IXIARO® revenues (growth of 17% (CER)) in Q1 2019
    • Total revenues were €34.9 million in Q1 2019
    • EBITDA of €8.2 million in Q1 2019
    • Net profit of €4.9 million in Q1 2019
    • Positive operating cash flow of €5.3 million
    • Strong cash position of €68.1 million at the end of March 2019

    Two significant R&D milestones reported in Q1 2019
    • Final Phase 1 data and first booster data for Lyme disease vaccine candidate, VLA15
    • Positive Phase 1 interim results for chikungunya vaccine candidate, VLA1553

    Press release
    Financial report
    Presentation
    Webcast link
    auf Deutsch lesen
  • Valneva to Present on Lyme and Chikungunya Vaccine Candidates at the 19th World Vaccine Congress2019-04-09

    Valneva to Present on Lyme and Chikungunya Vaccine Candidates at the 19th World Vaccine Congress

    Saint Herblain (France), April 9, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today it will present on its Lyme disease and chikungunya vaccine candidates on April 16th, 2019 at the 19th World Vaccine Congress in Washington, D.C.

    PDF Download
    auf Deutsch lesen
  • Valneva Announces Termination of 2013 Shareholder Agreement2019-04-03

    Valneva Announces Termination of 2013 Shareholder Agreement

    Saint Herblain (France), April 3, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today that the parties to the shareholder agreement executed on July 5, 2013 have decided not to renew it. Therefore, this agreement is due to expire on July 4, 2019.

    PDF Download
  • Valneva Announces the Publication of its 2018 Registration Document2019-03-25

    Valneva Announces the Publication of its 2018 Registration Document

    Saint Herblain (France), March 26, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today the publication of its 2018 Registration Document (“Document de Référence”), filed with the French Financial Market Authority (“Autorité des Marchés Financiers”) under the filing number D.19-0197 on March 25, 2019.

    PDF Download
  • Valneva Announces the Availability of its FY 2018 Audited Consolidated and Statutory Financial Statements2019-03-21

    Valneva Announces the Availability of its FY 2018 Audited Consolidated and Statutory Financial Statements

    Saint Herblain (France), March 21, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today the availability of its audited consolidated and statutory financial statements for the year ending December 31, 2018. The statements are available on the Company’s website https://www.valneva.com/en/investors-media/financial-reports.

    PDF Download
    2018 Annual Business Report
    2018 Consolidated Financial Statements (IFRS) (audited)
    2018 Statutory Financial Statements (audited)
    auf Deutsch lesen
  • Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 20192019-02-21

    Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019

    Major R&D milestones achieved in 2018, double-digit product sales revenue growth delivered; Lyme and chikungunya programs expected to advance further in 2019

    Saint Herblain (France), February 21, 2019 – Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, reported today its full year unaudited consolidated financial results for the year ending December 31, 2018.

    Press release
    2018 Consolidated financial statements (unaudited)
    Analyst presentation
    Webcast link
    auf Deutsch lesen
  • Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate2019-01-31

    Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate

    Saint-Herblain (France), January 31, 2019 – Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced positive initial booster data and final Phase 1 data for its leading, unique Lyme disease vaccine candidate VLA15.

    PDF Download
    auf Deutsch lesen
  • Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 20192019-01-16

    Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

    Saint Herblain (France), January 16, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, confirmed today its revenue and product sales guidance for 2018 and provided initial product sales guidance for 2019.

    PDF Download
    auf Deutsch lesen
  • Valneva Announces New $59 Million IXIARO® Supply Contract with US Government 2019-01-16

    Valneva Announces New $59 Million IXIARO® Supply Contract with US Government

    Saint Herblain (France), January 16, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today the signing of a new $59 million contract with the U.S. government Department of Defense for the supply of its Japanese encephalitis (JE) vaccine IXIARO®.

    PDF Download
    auf Deutsch lesen
  • Valneva Announces its Intention to Delist from the Vienna Stock Exchange2019-01-07

    Valneva Announces its Intention to Delist from the Vienna Stock Exchange

    Trading will be centralized on Euronext Paris

    Saint-Herblain (France), January 7, 2019 – Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today that it intends to delist from the Vienna Stock Exchange (VSE) in order to focus on the best capital markets for life science companies and increase liquidity by centralizing trading on Euronext Paris.

    PDF Download
    auf Deutsch lesen
  • Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate2019-01-07

    Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate

    Phase 1 interim results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile, supporting further development
    • 100% seroconversion rate achieved at Day 28 after a single-shot vaccination in a pooled analysis of all dose groups
    • Pooled analysis showed a high antibody response based on geometric mean titre
    • No serious adverse events or adverse events of special interest were reported up to Day 28

    PDF Download
    auf Deutsch lesen
Please update your browser...